Literature DB >> 14568476

Mapping of brain function after MPTP-induced neurotoxicity in a primate Parkinson's disease model.

Anna Liisa Brownell1, Kelly Canales, Y Iris Chen, Bruce G Jenkins, Christopher Owen, Elijahu Livni, Meixiang Yu, Francesca Cicchetti, Rosario Sanchez-Pernaute, Ole Isacson.   

Abstract

Neurophysiological studies of the brain in normal and Parkinson's disease (PD) patients have indicated intricate connections for basal ganglia-induced control of signaling into the motor cortex. To investigate if similar mechanisms are controlling function in the primate brain (Macaca fascicularis) after MPTP-induced neurotoxicity, we conducted PET studies of cerebral blood flow, oxygen and glucose metabolism, dopamine transporter, and D2 receptor function. Our observations after MPTP-induced dopamine terminal degeneration of the caudate and putamen revealed increased blood flow (15%) in the globus pallidus (GP), while blood flow was moderately decreased (15-25%) in the caudate, putamen, and thalamus and 40 % in the primary motor cortex (PMC). Oxygen extraction fraction was moderately increased (10-20%) in other brain areas but the thalamus, where no change was observable. Oxygen metabolism was increased in the GP and SMA (supplementary motor area including premotor cortex, Fig. 3) by a range of 20-40% and decreased in the putamen and caudate and in the PMC. Glucose metabolism was decreased in the caudate, putamen, thalamus, and PMC (range 35-50%) and enhanced in the GP by 15%. No change was observed in the SMA. In the parkinsonian primate, [(11)C]CFT (2beta-carbomethoxy-3beta-(4-fluorophenyltropane) dopamine transporter binding was significantly decreased in the putamen and caudate (range 60-65%). [(11)C]Raclopride binding of dopamine D(2) receptors did not show any significant changes. These experimental results obtained in primate studies of striato-thalamo-cortico circuitry show a similar trend as hypothetized in Parkinson's disease-type degeneration.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14568476     DOI: 10.1016/S1053-8119(03)00348-3

Source DB:  PubMed          Journal:  Neuroimage        ISSN: 1053-8119            Impact factor:   6.556


  21 in total

1.  Abnormal metabolic brain networks in a nonhuman primate model of parkinsonism.

Authors:  Yilong Ma; Shichun Peng; Phoebe G Spetsieris; Vesna Sossi; David Eidelberg; Doris J Doudet
Journal:  J Cereb Blood Flow Metab       Date:  2011-11-30       Impact factor: 6.200

2.  Reproducibility of a Parkinsonism-related metabolic brain network in non-human primates: A descriptive pilot study with FDG PET.

Authors:  Yilong Ma; Tom H Johnston; Shichun Peng; Chuantao Zuo; James B Koprich; Susan H Fox; Yihui Guan; David Eidelberg; Jonathan M Brotchie
Journal:  Mov Disord       Date:  2015-08       Impact factor: 10.338

3.  Anticipatory changes in regional cerebral hemodynamics: a new role for dopamine?

Authors:  Can Ozan Tan
Journal:  J Neurophysiol       Date:  2009-03-25       Impact factor: 2.714

4.  Primary motor cortex of the parkinsonian monkey: differential effects on the spontaneous activity of pyramidal tract-type neurons.

Authors:  Benjamin Pasquereau; Robert S Turner
Journal:  Cereb Cortex       Date:  2010-11-02       Impact factor: 5.357

5.  Enhanced binding of metabotropic glutamate receptor type 5 (mGluR5) PET tracers in the brain of parkinsonian primates.

Authors:  R Sanchez-Pernaute; J-Q Wang; D Kuruppu; L Cao; W Tueckmantel; A Kozikowski; O Isacson; A-L Brownell
Journal:  Neuroimage       Date:  2008-04-20       Impact factor: 6.556

6.  Modulation of Abnormal Metabolic Brain Networks by Experimental Therapies in a Nonhuman Primate Model of Parkinson Disease: An Application to Human Retinal Pigment Epithelial Cell Implantation.

Authors:  Shichun Peng; Yilong Ma; Joseph Flores; Michael Cornfeldt; Branka Mitrovic; David Eidelberg; Doris J Doudet
Journal:  J Nucl Med       Date:  2016-04-07       Impact factor: 10.057

Review 7.  Brain network markers of abnormal cerebral glucose metabolism and blood flow in Parkinson's disease.

Authors:  Shichun Peng; David Eidelberg; Yilong Ma
Journal:  Neurosci Bull       Date:  2014-09-28       Impact factor: 5.203

Review 8.  Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease.

Authors:  Gunasingh J Masilamoni; Yoland Smith
Journal:  J Neural Transm (Vienna)       Date:  2017-08-31       Impact factor: 3.575

9.  Low Cerebral Glucose Metabolism: A Potential Predictor for the Severity of Vascular Parkinsonism and Parkinson's Disease.

Authors:  Yunqi Xu; Xiaobo Wei; Xu Liu; Jinchi Liao; Jiaping Lin; Cansheng Zhu; Xiaochun Meng; Dongsi Xie; Dongman Chao; Albert J Fenoy; Muhua Cheng; Beisha Tang; Zhuohua Zhang; Ying Xia; Qing Wang
Journal:  Aging Dis       Date:  2015-11-17       Impact factor: 6.745

10.  Altered neuronal activity relationships between the pedunculopontine nucleus and motor cortex in a rodent model of Parkinson's disease.

Authors:  Bhooma R Aravamuthan; Debra A Bergstrom; Robin A French; Joseph J Taylor; Louise C Parr-Brownlie; Judith R Walters
Journal:  Exp Neurol       Date:  2008-06-09       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.